Netris pharma - About the company
Netris pharma is a series A company based in Lyon (France), founded in 2008. It operates as a Developer of therapeutic solutions to treat cancer. Netris pharma has raised $8.21M in funding from EIC Fund. The company has 3366 active competitors, including 1136 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of therapeutic solutions to treat cancer. The company is developing a pipeline of drugs targeting different ligands of dependence receptors. Its lead candidate is NP137 a monoclonal antibody that targets netrin-1, for the treatment of cancer.
- Website
- www.netrispharma.com/
- Email ID
- *****@netrispharma.com
Key Metrics
Founded Year
2008
Location
Lyon, France
Stage
Series A
Total Funding
$8.21M in 3 rounds
Latest Funding Round
Ranked
709th among 3366 active competitors
Employee Count
1 as on Jul 31, 2026
Similar Companies
Sign up to download Netris pharma's company profile
Netris pharma's funding and investors
Netris pharma has raised a total funding of $8.21M over 3 rounds. Its first funding round was on Jul 06, 2016. Its latest funding round was a Series A round on Dec 20, 2023 for $*****. 1 investor participated in its latest round. Netris pharma has 4 institutional investors.
Here is the list of recent funding rounds of Netris pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 20, 2023 | 4777508 | Series A | 8007016 | 1681324 | 3802674 | 4800948 |
2021 | 2392 | Grant (prize money) | 1973 | 2214 | 8128 | |
Jul 06, 2016 | 9493029 | Grant (prize money) | 1079050 | 4283723 | 5063707 | 3319005 |
Access funding benchmarks and valuations. Sign up today!View details of Netris pharma's funding rounds and investors
Netris pharma's founders and board of directors
Founder? Claim ProfileNetris pharma's employee count trend
Netris pharma has 1 employees as of Jul 26. Here is Netris pharma's employee count trend over the years:
Uncover Netris pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Netris pharma's Competitors and alternates
Top competitors of Netris pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Netris pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
709th | Netris pharma 2008, Lyon (France), Series A | Developer of therapeutic solutions to treat cancer | $8.21M | 47/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Netris pharma's competitors? Click here to see the top ones
Netris pharma's Investments and acquisitions
Netris pharma has made no investments or acquisitions yet.
Reports related to Netris pharma
Here is the latest report on Netris pharma's sector:
News related to Netris pharma
Media has covered Netris pharma for 1 event in last 1 year.
•
NETRIS Pharma Secures €7.25 Million in Horizon Europe Funding to Advance Phase 2b Clinical Trial in Head and Neck CancerEIN Presswire•May 28, 2026•Netris pharma
•
XENON Systems Partners with Netris to Deliver Multi-tenant GPU Cloud Networking Solutions for AI/ML Cloud Providers in the RegionBusiness Wire•Feb 12, 2025•Netris pharma, XENON Systems, Netris
•
NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor ResistanceACROFAN•Nov 28, 2022•Netris pharma
•
NETRIS Pharma, Orano and Centre Léon Bérard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate TherapiesBusiness Wire•Sep 20, 2022•Netris pharma, Orano, Centreleonberard
•
•
•
•
•
EastGate Biotech Announces Joint Venture With Netris/Origin Biopharmaceuticals for Pakistani Marketpharmacychoice.com•Apr 17, 2018•Netris pharma, EastGate Biotech
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Netris pharma
Explore our recently published companies
- Jts Animal - United States based, Unfunded company
- Indo Global Education Foundation - India based, 2003 founded, Unfunded company
- Blueprint Smiles - Atlanta based, 2013 founded, Unfunded company
- Bookboard - San Francisco based, Unfunded company
- Climate Wise - Unfunded company
- Doug Ashy Building Materials - United States based, 1960 founded, Unfunded company
